Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALF: TKI Withdrawal in CML
NCT04147533Phase 2Active, not recruiting
- Sponsor
- Masaryk University
- Start
- Jun 2020
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, dasatinib and nilotinib in chronic myeloid leukemia (CML), sponsored by Masaryk University. Primary endpoints: Major Molecular Response at 36 months, Molecular Recurrence-Free Survival at 36 months and 2 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04147533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147533.